Inhibition of cyclic AMP phosphodiesterases by cyclic nucleotide analogs and nitrogen heterocycles. 1984

J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins

UI MeSH Term Description Entries
D009712 Nucleotides, Cyclic Cyclic Nucleotide,Cyclic Nucleotides,Nucleotide, Cyclic
D006571 Heterocyclic Compounds Cyclic compounds that include atoms other than carbon in their ring structure. Heterocyclic Compound,Compound, Heterocyclic,Compounds, Heterocyclic
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015105 3',5'-Cyclic-AMP Phosphodiesterases Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. 3',5'-Cyclic AMP 5'-Nucleotidohydrolase,3',5'-Cyclic-Nucleotide Phosphodiesterase,CAMP Phosphodiesterase,3',5' Cyclic AMP Phosphodiesterase,3',5'-Cyclic AMP Phosphodiesterase,3',5'-Cyclic Nucleotide Phosphodiesterase,3',5'-Cyclic-AMP Phosphodiesterase,3',5'-Nucleotide Phosphodiesterase,3,5-Cyclic AMP 5-Nucleotidohydrolase,3,5-Cyclic AMP Phosphodiesterase,3',5' Cyclic AMP 5' Nucleotidohydrolase,3',5' Cyclic AMP Phosphodiesterases,3',5' Cyclic Nucleotide Phosphodiesterase,3',5' Nucleotide Phosphodiesterase,3,5 Cyclic AMP 5 Nucleotidohydrolase,3,5 Cyclic AMP Phosphodiesterase,5'-Nucleotidohydrolase, 3',5'-Cyclic AMP,5-Nucleotidohydrolase, 3,5-Cyclic AMP,AMP 5'-Nucleotidohydrolase, 3',5'-Cyclic,AMP 5-Nucleotidohydrolase, 3,5-Cyclic,AMP Phosphodiesterase, 3',5'-Cyclic,AMP Phosphodiesterase, 3,5-Cyclic,Nucleotide Phosphodiesterase, 3',5'-Cyclic,Phosphodiesterase, 3',5'-Cyclic AMP,Phosphodiesterase, 3',5'-Cyclic Nucleotide,Phosphodiesterase, 3',5'-Cyclic-AMP,Phosphodiesterase, 3',5'-Cyclic-Nucleotide,Phosphodiesterase, 3',5'-Nucleotide,Phosphodiesterase, 3,5-Cyclic AMP,Phosphodiesterase, CAMP,Phosphodiesterases, 3',5'-Cyclic-AMP

Related Publications

J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins
February 1995, Molecular pharmacology,
J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins
November 2015, FEMS microbiology letters,
J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins
January 2014, The Journal of general physiology,
J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins
November 1974, Arzneimittel-Forschung,
J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins
January 1992, Advances in second messenger and phosphoprotein research,
J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins
January 2011, Handbook of experimental pharmacology,
J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins
September 1975, Biochimica et biophysica acta,
J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins
February 1985, Life sciences,
J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins
November 2001, The Journal of allergy and clinical immunology,
J P Miller, and C C Sigman, and H L Johnson, and T Novinson, and R H Springer, and K Senga, and D E O'Brien, and R K Robins
January 1973, Advances in cyclic nucleotide research,
Copied contents to your clipboard!